37 reports of this reaction
4.0% of all CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, manufactured by Actavis Pharma, Inc.. There are 37 FDA adverse event reports linking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE to FATIGUE. This represents approximately 4.0% of all 933 adverse event reports for this drug.
Patients taking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 37 FDA reports for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.0% of all adverse event reports for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, making it one of the most commonly reported side effect.
If you experience fatigue while taking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.